Timing the switch from Tysabri to Gilenya

A study has been published showing that a shorter washout time when changing from treatment with natalizumab (Tysabri) to fingolimod (Gilenya) reduces the risk of relapse. MS Research Australia Natalizumab (Tysabri) - A to Z of MS Fingolimod (Gilenya) - A to Z of MS
Source: Multiple Sclerosis Trust - Category: Neurology Source Type: news